More than 4,000 Attend World Congress

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

VANCOUVER, BC-More than 4,000 pain experts from all over the world attended the International Association for the Study of Pain (IASP) 8th World Congress on Pain, at the Vancouver Trade and Convention Centre.

VANCOUVER, BC-More than 4,000 pain experts from all over the worldattended the International Association for the Study of Pain (IASP)8th World Congress on Pain, at the Vancouver Trade and ConventionCentre.

"The Congress is an opportunity for pain researchers andclinicians to discuss the latest advances in the field,"said IASP president John D. Loeser, MD, of the University of Washington."It's only within the last 20 years that medical sciencehas developed advanced assessment tools and intervention strategiesto reduce pain and suffering," he said.

The 8th World Congress was dedicated to the memory of ProfessorJohn J. Bonica who pioneered the multi-disciplinary approach topain management with the establishment in 1961 of the Universityof Washington Multidisciplinary Pain Center.

Dr. Loeser is the Center's current director.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content